KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in combination with Platinum doublet chemotherapy as first-line(1L) treatment in patients with advanced NSCLC harboring resistant oncogenic driver alterations
KN-046
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in combination with Platinum doublet chemotherapy as first-line(1L) treatment in patients with advanced NSCLC harboring resistant oncogenic driver alterations ### Output: KN-046